ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.255
0.12%
US Dollar vs AUD
1.52765
-0.35%
Bitcoin
64,419.43
-0.10%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Addex Therapeutics Ltd (ADXN)

  7. Addex Therapeutics Ltd (ADXN) News

ADXN Addex Therapeutics Ltd

15.41
-0.14 (-0.90%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Addex Therapeutics Ltd ADXN NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.14 -0.90% 15.41 10:00:00
Open Price Low Price High Price Close Price Previous Close
15.33 15.20 16.10 15.41 15.55
more quote information »

Recent News

Date Time Source Heading
19/4/202415:00GLOBEAddex to Present at the Swiss Biotech Day 2024
18/4/202415:00GLOBEAddex Therapeutics Reports Full Year 2023 Financial Results..
11/4/202415:00GLOBEAddex Therapeutics to Release Full-Year 2023 Financial..
03/4/202416:00GLOBEAddex and Perceptive Launch Neurosterix with $63 Million to..
14/3/202417:00GLOBEAddex to Present at the Bio-Europe Spring 2024 Conference
31/1/202417:00GLOBEAddex Enters into At-The-Market ADS Offering Agreement with..
31/1/202409:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/1/202408:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202417:00GLOBEAddex to Present at the Swiss Equities Baader Conference
05/1/202417:30GLOBEAddex to Present at Biotech Showcase™ 2024
21/12/202322:00EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202317:00GLOBEAddex Shareholders Approve All Resolutions at Extraordinary..
14/12/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202317:00GLOBEAddex Creates Treasury Shares
09/12/202306:11EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202308:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/11/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
30/11/202308:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29/11/202322:27EDGAR2Form POS AM - Post-Effective amendments for registration..
29/11/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202317:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28/11/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202317:00GLOBEAddex Convenes Extraordinary General Meeting
23/11/202317:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14/11/202317:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08/11/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202317:00GLOBEAddex Regains Nasdaq Listing Compliance
02/11/202317:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
23/10/202321:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/10/202321:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/10/202316:00GLOBEAddex Completes ADS Ratio Change
07/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/10/202307:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20/9/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06/9/202315:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05/9/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202315:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04/9/202315:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
12/8/202306:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/8/202306:00EDGAR2Form POS AM - Post-Effective amendments for registration..
10/8/202320:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202315:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04/8/202315:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03/8/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202315:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24/7/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202315:00GLOBEAddex mGlu2PAM Demonstrates Potential in Substance Use..

Your Recent History

NASDAQ
ADXN
Addex Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved